Objective. To investigate whether anticardiolipin (aCL) and anti-b 2 -glycoprotein I (antib 2 GPI ) antibodies are associated with lupus nephritis (group II patients), and whether there are differences in the prevalence of these two autoantibodies between group II patients and patients with non-nephritis SLE (group I ) and primary antiphospholipid syndrome (PAPS) patients (group III ).
Raised blood levels of antiphospholipid (aPL) antibodies assays. This cofactor has been identified as in autoimmune diseases and especially in systemic lupus b 2 -glycoprotein I ( b 2 GPI ) [9] [10] [11] . It has been shown erythematosus (SLE), in which levels of these autoantisubsequently that b 2 GPI is able to bind to activated bodies are raised in 20-60% of patients, have been polystyrene plates as an antigen and can be used to associated with recurrent venous and arterial thromfacilitate the detection of specific anti-b 2 GPI antibodies boses, fetal loss, thrombocytopenia and neurological in patient sera [12] . This has led to a number of studies disorders [1] [2] [3] [4] [5] . A separate and distinct syndrome, the in which these autoantibodies have been reported to primary antiphospholipid syndrome (PAPS), has been occur in 5-82% of SLE and PAPS patients [13] [14] [15] [16] . recognized in which patients have raised aPL levels and Although a number of studies have examined levels at least one of the clinical complications associated with of aCL [3-5, 17] and anti-b 2 GPI [14, 18] in lupus these antibodies, but no other overt feature of SLE or nephritis patients, no association has been reported another autoimmune disease [6] [7] [8] .
between autoantibody levels and this clinical complicaRecently, three independent groups have reported tion; a negative association has, however, been reported that, in PAPS patients, anticardiolipin antibodies (aCL) for aCL in lupus nephritis by two independent groups need a circulating plasma protein as a cofactor, which [19, 20] . binds to the cardiolipin antigen in solid-phase ELISA The present study was undertaken to establish validated ELISA assays for the ascertainment of the prevalence of IgG and IgM aCL and anti-b 2 GPI antibodies (anti-dsDNA) and the collagenous region of C1q (antiand IgM aCL antibodies were detected using alkaline phosphatase-conjugated antibodies against human IgG C1q antibodies). For comparative purposes, all these autoantibodies were also measured in a group of PAPS (c chain-specific) or IgM ( m chain-specific); the concentration of aCL was measured at 405 nm, after addition patients, in whom nephritis is seldom present as a clinical complication; in such patients the presence of of p-nitrophenyl phosphate chromogenic substrate, on a microplate spectrophotometer ( Titertek Multiscan immune complex-related glomerulonephritis is quoted as one of the exclusion criteria for the diagnosis of MCC/340; Life Sciences International ); aCL levels were calculated from an eight-point standard curve in arbit-PAPS [21] .
Our results indicated that aCL antibodies are more rary ELISA units (AEU ), and serum internal control samples with low and high aCL levels were placed at prevalent than anti-b 2 GPI antibodies in SLE patients with nephritis. We have also found that elevated levels the beginning and end of each plate to monitor assay performance. of aCL antibodies in combination with raised antidsDNA and anti-C1q antibodies are highly specific markers for nephritis in SLE, whereas anti-b 2 GPI antiAnti-b 2 GPI ELISA bodies are not.
For the IgG and IgM anti-b 2 GPI assay, duplicate wells on high-binding microtitre plates (Immulon 2; Dynatech
Patients and methods
Laboratories, Billingshurst, UK ), were coated with 50 ml of the purified b 2 GPI preparation (5 mg/ml ) in 0.2  Assays were performed on stored serum samples borate-buffered saline (BBS); single adjacent wells were (−70°C ) from 25 unselected SLE patients (24 female, 1 coated with BBS alone for the estimation of non-specific male, age range 20-71 years, median 43 years; group binding for all serum samples, standards and controls. I ), none of whom had had any evidence of nephritis,
Plates were subsequently blocked with 0.5% and from 31 SLE patients (29 female, 2 male; age range BSA/PBS/0.4% Tween-20 for 2 h at room temperature. 17-61 years, median 31 years; group II ). All samples Serum samples, standards and controls (at 1:100 dilufrom group II patients were taken during an active tion), 50 ml/well (all diluted in 0.5% BSA/PBS/0.4% phase of nephritis (proteinuria, impaired renal function, Tween-20), were then added and incubated at room histologically proven WHO GN types I-VI ). All 56 temperature for 1 h; this was followed by addition of SLE patients fulfilled the American College of alkaline phosphatase-conjugated goat F(ab∞) 2 fragments Rheumatology revised criteria for the classification of of anti-human c-chain-specific IgG or m-chain-specific SLE [22] . Serum samples were also taken from 36
IgM (Sigma, Poole, Dorset, UK ), and addition of patients with PAPS, only two of whom had documented chromogenic substrate as described above for the aCL evidence of renal disease, and all of whom were aCLassay. All washing steps in the assay were performed positive and had had at least one of the clinical complicawith PBS/0.075% Tween-20. The optical absorbance of tions associated with PAPS (29 female, 7 male, age the appropriate non-specific binding was subtracted range 20-72 years, median 38 years; group III ), and from all readings for patient samples, standards and from 88 normal blood donors.
controls before the final levels of IgG and IgM antib 2 GPI in AEU were calculated from an eight-point Human b 2 GPI standard curve. Internal controls were included on each The b 2 GPI preparation used was purified from normal plate to monitor assay performance. human serum using a modification of the precipitation method of Polz [23] followed by affinity chromatoAnti-C1q antibodies graphy on a heparin-Sepharose (Hitrap), column and protein G columns (Amersham Pharmacia, St Albans,
The ELISA for anti-C1q IgG was based on a method described previously [26 ] . UK ), as described by Matsuura [24] . Purity was assessed on the butanol delipidated preparation by SDS-PAGE, double radial immunodiffusion, and ELISA using a Anti-dsDNA antibodies rabbit anti-human b 2 GPI-specific antibody (Dako, Anti-dsDNA antibodies were measured by the Farr Ely, UK ).
assay [27] . Positivity was set as >30% binding.
Anticardiolipin antibody assays
Normal autoantibody levels Estimation of aCL IgG and IgM was performed as described previously [25] , with minor modifications.
Patient sera were considered positive for IgG and IgM aCL and anti-b 2 GPI antibodies when autoantibody Essentially, plain polystyrene microtitre plates (MP01; Life Sciences International, Basingstoke, UK ) were levels were 4 standard deviations (SDs) above the mean level of the 88 healthy normal blood donors. For aCL coated with cardiolipin (2 mg/well ) in ethanol and allowed to evaporate to dryness at 4°C. Plates were this was <14.0 AEU for IgG and <10.0 AEU for IgM; for anti-b 2 GPI it was <12.6 AEU for IgG and <9.5 blocked with a 5% solution of adult bovine serum in phosphate-buffered saline (ABS/PBS), followed by addifor IgM. For IgG anti-C1q antibodies the cutoff point was set at 3 SDs above the mean level of 50 normal tion of 100 ml diluted serum samples, standards and controls (at 1:100 dilution) in ABS/PBS. Bound IgG controls, which corresponded to <20 AEU.
Statistical analysis
Statistical analysis was performed using the Prism v2.0 software package (GraphPad Software, San Diego, CA, USA). Differences between proportions of autoantibodies were assessed using the x2 test. The MannWhitney U-test and the Spearman's rank sum test were used to analyse aCL and anti-b 2 GPI isotypes in the three patient groups.
Results

Prevalence of aCL and anti-b
2 GPI antibodies The prevalence and isotype distribution of aCL and anti-b 2 GPI antibodies are shown in Table 1 . Among the 25 patients without nephritis (group I ), a total of 12 (48%) were positive (for IgG and/or IgM aCL), in contrast to 24 (77.4%) of the 31 lupus nephritis patients (group II ) and all the PAPS patients ( Table 1) . The difference in aCL positivity between groups I and II was F. 1. Levels of anticardiolipin antibodies (aCL), IgG and/or significant ( x2 = 5.2130, P < 0.02). Absolute aCL levels IgM, whichever was the highest, in SLE patients with (group (IgG and/or IgM ) were compared in the two SLE I ), without nephritis (group II ) and PAPS patients. patient groups, and were found to be significantly higher Mann-Whitney U-test: group I vs group II, P < 0.02.
in group II than in group I patients (P = 0.02, Mann-
Whitney U-test) ( Fig. 1) .
Anti-b 2 GPI antibodies (IgG and/or IgM anti-b 2 GPI ) were positive in seven patients (28%) in group I, in eight positive/aCL-negative (specific anti-b 2 GPI antibodies or b 2 GPI-dependent aCL), a significant difference was seen of 30 patients (26.7%) in group II and in 16 patients (44.4%) in group III. Anti-b 2 GPI levels were raised, and only between group I and group III patients ( x2 = 7.8427, P < 0.01). Both autoantibodies ( b 2 GPIwere significantly higher in group III patients when compared with group I (P = 0.0004), and group II dependent and b 2 GPI-independent aCL) were present in two patients (8%) in group I, five patients (16.7%) in (P =0.0002) patients using the Mann-Whitney U-test (Fig. 2) .
group II and 16 patients (44.4%) in group III. There was a significant difference in the number of positive Relationship between aCL and anti-b 2 GPI antibodies patients between group III and groups 1 ( x2 = 10.58, P < 0.01) and 2 (x2 = 6.87, P = 0.01). The relationships between aCL and anti-b 2 GPI antibodies are shown in Table 1 . No significant difference Levels of IgG and IgM aCL and anti-b 2 GPI antibodies were analysed for possible relationships by was observed in aCL-positive/anti-b 2 GPI-negative ( b 2 GPI-independent aCL) patients in the three patient Spearman's rank correlation test (data not shown). Significant positive correlations were found in group I groups. In contrast, for patients who were anti-b 2 GPI None of the patients in group I and only two of the 36 PAPS patients in group III had documented evidence of renal disease. Levels of aCL were raised in 12 patients (48%) in group I, in 24 patients (77.4%) in group II and in all 36 patients (100%) in group III, in which all patients were chosen for their aCL positivity. The difference in the number of positive patients between groups I and II ( x2 = 5.2167, P < 0.02) was significant. For anti-C1q antibodies, there were five positive patients (20%) in group I, 20 (64.5%) in group II and none in group III. The differences between groups I and II ( x2 = 11.097, P < 0.001), groups I and III ( x2 = 7.9853, P < 0.01) and groups II and III ( x2 = 33.109, P < 0.001) were highly significant; anti-C1q antibody levels were significantly higher in group II patients than in groups I (P = 0.0002) and III (P = 0.0001, Mann-Whitney Utest) (data not shown). For anti-dsDNA antibodies, I and II ( x2 = 13.531, P < 0.001), between groups I and group III vs group II, P < 0.002. <$ = aCL-positive;
III ( x2 = 6.8571) and between groups II and III # = aCL-negative.
( x2 = 37.840, P < 0.001). Anti-dsDNA levels varied between the patient groups and were significantly higher between IgG and/or IgM aCL and IgG and/or IgM in group II than in groups I (P < 0.001) and III anti-b 2 GPI levels (P = 0.05). In group II, the only (P < 0.0001, Mann-Whitney U-test) (data not shown). correlation seen was between IgM aCL and IgM antiWhen possible correlations (Spearman's rank sum b 2 GPI levels (P = 0.05). In PAPS patients, positive test) between pairs of individual autoantibodies were correlations were seen between IgG aCL and IgG antiinvestigated in the three different patient groups, the b 2 GPI (P = 0.0001), IgM aCL and IgM anti-b 2 GPI only correlation found was between aCL and anti-(P = 0.005), and invariably between IgG and/or IgM dsDNA antibody levels in group II lupus nephritis aCL and IgG and/or IgM anti-b 2 GPI levels (P = 0.001). patients (P < 0.005). The relationship between anti-C1q and aCL levels in lupus nephritis did not reach statistical Relationship between aCL, anti-b 2 GPI anti-C1q and significance (P = 0.07) (data not shown). When the anti-dsDNA antibodies and lupus nephritis number of patients positive for all three autoantibodies The relationship between the number of patients with shown in Table 2 was investigated, only one patient elevated levels of aCL, anti-b 2 GPI, anti-C1q and anti-(4%) was positive in group I, 16 patients (51.6%) were dsDNA antibodies and nephritis was investigated, and positive in group II and none was positive in group III. the results are summarized in Table 2 . As none of the Highly significant differences were found in the number anti-b 2 GPI antibody-positive patients in any of the three of patients positive for all three autoantibodies between groups was also positive for the other three autoantigroups II and I ( x2 = 14.839, P < 0.001) and between groups II and III ( x2 = 23.845, P < 0.001). bodies measured, they have been excluded from Table 2 . x2 = 33.109 P < 0.001 P < 0.001 Anti-dsDNA-positive 9 (36) 26 (83.9) 3/35 (13) x2 = 13.531 x2 = 37.840 P < 0.001 P < 0.001 Positive for all three 1 (4) 16 (51.6) 0 (0) autoantibodies x2 = 14.839 x2 = 23.845 P < 0.001
Relationship between aCL and anti-b 2 GPI antibodies and that the relevant antigen can be removed by heat and aPL-associated clinical features treatment, acid treatment, hypermolar buffers or phospholipase enzymes [29] . We examined the relationship between aCL and antiIn the present study, using validated ELISA assays b 2 GPI antibodies and the aPL-associated clinical manifor the measurement of IgG and IgM aCL and antifestations of thrombosis (venous and arterial ), b 2 GPI antibody levels, we have examined the relationthrombocytopenia (platelet count <120 000/ml ) and ship between these two autoantibodies in SLE patients fetal loss (more than one fetal loss) in our three groups with and without nephritis, and compared them with of patients, and our findings are summarized in Table 3. those found in PAPS patients, only two of whom had The number of patients positive for aCL or anti-b 2 GPI documented evidence of nephritis ( Table 1) . We noted with these complications was often too low for meaninga much higher prevalence and significantly higher levels ful statistical evaluation. For thrombotic complications, for IgG and/or IgM aCL in SLE patients with active we found that patients with this complications in group nephritis (group I ) than in patients without nephritis II (85.7%) were more likely to be positive for aCL (group II, P < 0.02), and, as previously described [13], than group I patients (60%). The same was true for a larger but not statistically significant difference in the thrombocytopenia (100 vs 66.7%) and fetal loss (100 prevalence of anti-b 2 GPI between group III and groups vs 50%); these relationships could not be assessed in I and II. Anti-b 2 GPI levels were significantly higher in our PAPS patients, who by definition were all chosen group III than in groups I (P < 0.004) and II (P < 0.002) for their aCL positivity and the presence of at least one ( Fig. 2) . Differences in isotype distribution and positivof these clinical complications. For PAPS patients on ity were also seen between our three patient groups for the whole, patients who were anti-b 2 GPI-positive were both autoantibodies ( Discussion one study reported associations between IgG aCL and SLE nephritis [30] similar to those we found. In contrast, Raised levels of circulating antiphospholipid antibodies another study, which appeared at the same time, found (anticardiolipin) have been strongly associated with an inverse (negative) correlation between antiphospholiarterial and venous thrombosis, thrombocytopenia and pid antibodies and SLE nephritis [19] , and a later study recurrent fetal loss in SLE and PAPS patients [1-6 ]; reported no association at all and a lower prevalence more recently, thrombosis has also been associated with (43%) than ours (77.4%) for aCL [17] ; this difference raised levels of anti-b 2 GPI antibodies in both these could be due to differences in the methods used and patient groups, especially in PAPS patients [13] [14] [15] [16] . patient selection. In our ELISA for aCL we incorporate Despite the numerous reports that have appeared adult bovine serum (containing b 2 GPI ) in both blocking describing clinical complications and their association and diluent solutions, whereas the earlier study used a with these two autoantibodies, very little has been blocking solution containing purified BSA (with very reported regarding the clinical significance of raised little or no b 2 GPI ) in their aCL assay. It could be, levels of aCL and/or anti-b 2 GPI antibodies and SLE therefore, that we measured both b 2 GPI-dependent and nephritis [14, 17, 18] , a common clinical manifestation b 2 GPI-independent aCL ( Table 1) , whereas the earlier of lupus [21, 28] . Although the pathogenetic role of study had measured only b 2 GPI-independent aCL [31] . aCL in lupus nephritis is still not clear [21] , recent Our patient samples were collected from SLE patients evidence has suggested that 'hidden' b 2 GPI-independent during an active phase of nephritis, whereas both the antibodies to negatively charged phospholipids may circulate as immune complexes in normal human serum, earlier study [17] and a more recent study, which reported a lower aCL prevalence of 38% in SLE nephritis more likely to be positive for all three autoantibodies than non-nephritis SLE or PAPS patients. We feel that, patients [28], did not indicate whether aCL was measured during an active phase of nephritis in their SLE from the results shown in Table 1 , we can infer that many more of our SLE patients (groups I and II ) patients. Our findings for anti-b 2 GPI antibodies are in agreement with those reported in previous studies that have b 2 GPI-independent than b 2 GPI-dependent aCL antibodies. had also failed to find an association between antib 2 GPI levels and renal disease in SLE patients [14, 18] . The association found for aCL, but not for antib 2 GPI, with lupus nephritis was further strengthened by On examining the relationship between aCL and antib 2 GPI levels, the only significant correlations seen using the strong association seen when aCL positivity in conjunction with positivity for anti-dsDNA and antithe Spearman's rank correlation test were between aCL and anti-b 2 GPI IgG and/or IgM in patients with nephC1q antibodies was examined; their presence and levels in serum could act as useful markers of the severity of ritis (P < 0.05) and between aCL and anti-b 2 GPI IgM in patients without nephritis (P < 0.05). In contrast, renal disease, as we found that lupus nephritis patients were much more likely to be positive for all three correlations were found in PAPS patients between the IgG (P < 0.001) and IgM isotypes (P < 0.005) for both autoantibodies than non-nephritis SLE or PAPS patients. Further prospective studies monitoring the autoantibodies, a strong correlation was also found between aCL and anti-b 2 GPI IgG and/or IgM levels of these three autoantibodies could be very useful in determining disease activity and in predicting the (P < 0.005) and in PAPS patients ( Table 2) . Our findings are similar to those reported in two previous studies, development of nephritis in SLE. which had also found significant correlations between aCL and anti-b 2 GPI antibody levels [12, 14] .
